EMA Authorised: Clopidogrel Krka d.d. (previously Zopya) (clopidogrel (as hydrochloride)) — Norpharm Regulatory Services Ltd

View source ↗

Summary

The EMA authorised Clopidogrel Krka d.d. for indications including peripheral vascular disease, stroke, and myocardial infarction; the marketing authorisation h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction
• Peripheral Vascular Disease
• Stroke

Drugs mentioned

• Clopidogrel Krka d.d. (clopidogrel)

Snippet

Status: Authorised. Therapeutic area: Peripheral Vascular Diseases;Stroke;Myocardial Infarction. MAH: Norpharm Regulatory Services Ltd. Decision date: 13/05/2025